다우존스 지수

같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

등록

VSTM

Verastem (VSTM)

Verastem Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:VSTM

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/04/19	05:05	Business Wire	Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer	NASDAQ:VSTM	Verastem Inc
2024/04/04	20:30	Business Wire	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:VSTM	Verastem Inc
2024/03/18	20:00	Business Wire	Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer	NASDAQ:VSTM	Verastem Inc
2024/03/15	05:05	Business Wire	Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates	NASDAQ:VSTM	Verastem Inc
2024/03/12	06:07	Edgar (US Regulatory)	Form SC TO-I/A - Tender offer statement by Issuer: [Amend]	NASDAQ:VSTM	Verastem Inc
2024/03/11	20:30	Business Wire	Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs	NASDAQ:VSTM	Verastem Inc
2024/03/06	07:27	Business Wire	Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer	NASDAQ:VSTM	Verastem Inc
2024/03/06	06:30	Business Wire	Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024	NASDAQ:VSTM	Verastem Inc
2024/02/09	06:22	Edgar (US Regulatory)	Form SC TO-I - Tender offer statement by Issuer	NASDAQ:VSTM	Verastem Inc
2024/02/02	23:49	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:VSTM	Verastem Inc
2024/01/30	06:01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VSTM	Verastem Inc
2024/01/29	21:00	Business Wire	Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers	NASDAQ:VSTM	Verastem Inc
2024/01/19	21:54	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VSTM	Verastem Inc
2024/01/19	06:00	Business Wire	Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)	NASDAQ:VSTM	Verastem Inc
2024/01/11	21:00	Business Wire	Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference	NASDAQ:VSTM	Verastem Inc
2024/01/10	06:03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VSTM	Verastem Inc
2024/01/09	06:02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VSTM	Verastem Inc
2024/01/05	21:00	Business Wire	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:VSTM	Verastem Inc
2023/12/29	06:04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VSTM	Verastem Inc
2023/12/22	06:01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VSTM	Verastem Inc
2023/12/21	06:01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VSTM	Verastem Inc
2023/12/21	06:00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VSTM	Verastem Inc
2023/12/20	06:01	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:VSTM	Verastem Inc
2023/12/18	21:00	Business Wire	Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics	NASDAQ:VSTM	Verastem Inc
2023/12/13	21:00	Business Wire	Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer	NASDAQ:VSTM	Verastem Inc
2023/12/09	06:10	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:VSTM	Verastem Inc
2023/11/21	14:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:VSTM	Verastem Inc
2023/11/13	21:00	Business Wire	New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach	NASDAQ:VSTM	Verastem Inc
2023/11/09	07:01	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:VSTM	Verastem Inc
2023/11/09	06:16	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:VSTM	Verastem Inc

검색 관련기사 보기:NASDAQ:VSTM

1 2 3 4 5 6 7 8 9 10 다음 >>

Deutsche Telekom (QX)

US Dollar vs Euro

Bank of America

Verizon Communications

Gold vs US Dollar

Financial Select Sector

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관